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Follicular lymphoma is the second most frequent type of non-
Hodgkin’s lymphoma in adults. The basic molecular defect consists in
the t(14;18)(q32;q21) translocation, juxtaposing the B-cell lymphoma
protein 2 gene BCL2 to the immunoglobulin heavy chain locus IGH@,
and leading to the antiapoptotic BCL2 protein over-production. Variations in the t(14;18) are rare and can be
classified into two categories: i)
simple variants, involving chromosomes 18 and 2, or 22, in which the
fusion partner of the BCL2 is the light-chain IGK@ or IGL@; ii) complex
variant translocations, occurring among chromosomes 14, 18, and other chromosomes. We report a follicular
lymphoma case showing BCL2
overexpression, detected by immunohistochemistry and Real-Time
Quantitative PCR, consequently to the formation of a novel fusion gene
between the 5’ of the lymphoid nuclear transcriptional activator gene
AFF3 at 2q11.2, and the 3’ of BCL2. The present case shows evidence,
for the first time, of BCL2 overexpression consequently to the fusion of
BCL2 to a non-IG partner locus.
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